A Phase 3 interventional study of Atorvastatin and Evolocumab in Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events, sponsored by Amgen. Completed at 54 sites in Japan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2015-12-23.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing evolocumab in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. evolocumab · Hyperlipidemias.
Among the 21 studies testing evolocumab in Hyperlipidemias, this one is the 9th largest by enrollment, is one of 7 that started in 2013, is one of 12 in phase 3, and was the 10th registered.
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
Browse Hyperlipidemias studies →None of the 21 studies testing evolocumab in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →
evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 20 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 7 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 409 is above the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 307 across the 21 interventional studies. Of the 20 that completed or were terminated, 19 (95%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 21 have an industry lead sponsor. The 6 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
17 studies in Hyperlipidemias by Amgen: none open now, none under way, none of them phase 3. Of 17 finished, 17 (100%) have results posted.
Among the 17 studies in Hyperlipidemias by Amgen, this one is the 9th largest by enrollment, is one of 7 that started in 2013, is one of 11 in phase 3, and was the 10th registered.
Amgen’s Hyperlipidemias studies by the year they started, since 2010.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing evolocumab in Hyperlipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 17 in Hyperlipidemias:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study was to evaluate the effect of 12 weeks of subcutaneous evolocumab administered every 2 weeks and once a month, compared with placebo, on percent change from baseline in LDL-C when used in combination with statin therapy in adults with high cardiovascular risk and with hyperlipidemia or mixed dyslipidemia.
After a screening and placebo run-in period, eligible patients were randomized in a 1:1 ratio to 1 of 2 open-label background statin treatments (atorvastatin 5 mg or 20 mg daily [QD]) and entered a 4-week lipid stabilization period. After the lipid stabilization period, eligible patients were randomized in a 1:1:1:1 ratio to investigational product (evolocumab or placebo) for the 12-week treatment period.
Both randomizations were stratified by subject diagnosis and lipid-lowering therapy as follows:
Inclusion Criteria: Male or female, Japanese adult, 20-85 years of age; Subjects on stable dose of statin for greater than equal to 4 weeks; Fasting LDL-C greater than equal to 100 mg/dL; Fasting triglycerides less than equal to 400 mg/dL; Subject is at high risk for cardiovascular events. Exclusion Criteria: (NYHA) III or IV - heart failure; Uncontrolled cardiac arrhythmia; Uncontrolled hypertension; Type 1 diabetes, poorly controlled type 2 diabetes; Uncontrolled hypothyroidism or hyperthyroidism
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received atorvastatin 5 mg (A5) once daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
Drug: Atorvastatin · Other: Placebo to Evolocumab
Participants received atorvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.
Drug: Atorvastatin · Other: Placebo to Evolocumab
Participants received atorvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
Drug: Atorvastatin · Biological: Evolocumab
Participants received atorvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.
Drug: Atorvastatin · Biological: Evolocumab
Participants received atorvastatin 20 mg (A20) once daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.
Drug: Atorvastatin · Other: Placebo to Evolocumab
Participants received atorvastatin 20 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.
Drug: Atorvastatin · Other: Placebo to Evolocumab
Participants received atorvastatin 20 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
Drug: Atorvastatin · Biological: Evolocumab
Participants received atorvastatin 20 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.
Drug: Atorvastatin · Biological: Evolocumab
Administered orally once a day
Also known as: Lipitor
Administered by subcutaneous injection
Also known as: AMG 145, Repatha
Administered by subcutaneous injection
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
Time frame: Baseline and Week 12
Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Change From Baseline in LDL-C at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Non-HDL-C at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Apolipoprotein B at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Total Cholesterol at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in the Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12
Time frame: Baseline and Week 12
Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL
Time frame: Weeks 10 and 12
Percentage of Participants Who Achieved LDL-C < 70 mg/dL at Week 12
Time frame: Week 12
Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Lipoprotein(a) at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Triglycerides at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in HDL-C at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in VLDL-C at Week 12
Time frame: Baseline and Week 12
Japanese men and women ≥ 20 to ≤ 85 years of age, with fasting low-density lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL (2.6 mmol/L), fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L), and at high risk for cardiovascular events were eligible to participate. First patient enrolled on 07 October 2013 and last patient enrolled on 17 February 2014.
| Milestone | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM |
|---|---|---|---|---|---|---|---|---|
| Started | 49 | 50 | 50 | 50 | 52 | 51 | 51 | 51 |
| Received treatment | 49 | 50 | 50 | 50 | 52 | 51 | 51 | 51 |
| Completed | 49 | 50 | 50 | 50 | 50 | 51 | 51 | 51 |
| Not completed | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| percent change | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at the Mean of Weeks 10 and 12 | 0.27 ± 2.21 | 3.91 ± 2.09 | -73.70 ± 2.26 | -69.98 ± 2.02 | -0.42 ± 3.26 | -2.67 ± 2.31 | -74.82 ± 3.26 | -76.93 ± 2.24 |
| percent change | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12 | 1.28 ± 2.43 | 5.29 ± 2.19 | -73.57 ± 2.48 | -64.62 ± 2.12 | 1.39 ± 3.51 | -3.49 ± 2.67 | -74.46 ± 3.50 | -70.36 ± 2.61 |
| mg/dL | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 | -14.8 ± 4.3 | -2.6 ± 4.3 | -104.1 ± 4.4 | -88.9 ± 4.1 | -8.9 ± 3.2 | -5.7 ± 3.7 | -77.6 ± 3.2 | -77.7 ± 3.6 |
| mg/dL | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in LDL-C at Week 12 | -13.7 ± 4.6 | -0.4 ± 4.3 | -104.5 ± 4.6 | -84.0 ± 4.2 | -7.7 ± 3.3 | -6.2 ± 4.0 | -77.2 ± 3.3 | -71.7 ± 3.9 |
| percent change | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12 | 0.18 ± 2.13 | 4.26 ± 1.86 | -68.48 ± 2.18 | -61.69 ± 1.80 | -1.57 ± 2.45 | -1.79 ± 1.94 | -69.72 ± 2.45 | -69.07 ± 1.88 |
| percent change | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 12 | 1.12 ± 2.30 | 5.55 ± 2.02 | -67.81 ± 2.35 | -58.03 ± 1.96 | -0.07 ± 2.68 | -2.38 ± 2.22 | -68.89 ± 2.67 | -63.27 ± 2.16 |
| percent change | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12 | -0.32 ± 1.98 | 0.76 ± 2.06 | -64.76 ± 2.03 | -58.47 ± 1.99 | -4.32 ± 2.27 | -0.85 ± 1.90 | -64.38 ± 2.27 | -64.24 ± 1.84 |
| percent change | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B at Week 12 | 0.74 ± 2.17 | 2.42 ± 2.26 | -64.83 ± 2.22 | -54.80 ± 2.19 | -2.47 ± 2.48 | -1.89 ± 2.17 | -62.83 ± 2.47 | -58.04 ± 2.11 |
| percent change | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12 | -2.49 ± 1.81 | 1.09 ± 1.63 | -48.03 ± 1.85 | -42.34 ± 1.58 | -4.21 ± 1.86 | -2.35 ± 1.68 | -45.19 ± 1.86 | -45.49 ± 1.63 |
| percent change | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Total Cholesterol at Week 12 | -1.70 ± 1.97 | 2.29 ± 1.67 | -47.14 ± 2.01 | -39.06 ± 1.62 | -3.08 ± 2.00 | -2.44 ± 1.81 | -44.04 ± 1.99 | -40.88 ± 1.76 |
| percent change | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12 | 3.77 ± 2.11 | 3.94 ± 2.16 | -51.00 ± 2.16 | -48.71 ± 2.09 | 1.04 ± 1.82 | 1.58 ± 2.04 | -49.79 ± 1.81 | -48.11 ± 1.98 |
| percent change | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12 | 4.73 ± 2.36 | 4.33 ± 2.33 | -50.72 ± 2.40 | -46.62 ± 2.26 | 1.84 ± 2.01 | 0.83 ± 2.20 | -49.52 ± 2.00 | -44.61 ± 2.13 |
| percent change | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at the Mean of Weeks 10 and 12 | 0.06 ± 2.02 | 2.79 ± 2.37 | -66.41 ± 2.07 | -61.55 ± 2.29 | -1.92 ± 2.30 | 1.54 ± 2.09 | -65.97 ± 2.30 | -65.72 ± 2.02 |
| percent change | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in the Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12 | 0.71 ± 2.11 | 4.08 ± 2.62 | -67.59 ± 2.16 | -58.45 ± 2.53 | -1.15 ± 2.47 | 0.06 ± 2.30 | -65.11 ± 2.46 | -60.56 ± 2.23 |
| percentage of participants | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL | 0.0 ± 2.02 | 0.0 ± 2.37 | 98.0 ± 2.07 | 96.0 ± 2.29 | 22.4 ± 2.30 | 15.7 ± 2.09 | 96.0 ± 2.30 | 98.0 ± 2.02 |
| percentage of participants | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved LDL-C < 70 mg/dL at Week 12 | 0.0 ± 2.02 | 4.2 ± 2.37 | 98.0 ± 2.07 | 96.0 ± 2.29 | 20.4 ± 2.30 | 20.0 ± 2.09 | 96.0 ± 2.30 | 98.0 ± 2.02 |
| percent change | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12 | 5.23 ± 6.18 | 4.07 ± 4.95 | -45.97 ± 6.27 | -45.01 ± 4.78 | 6.52 ± 4.81 | -5.62 ± 5.00 | -43.03 ± 4.81 | -49.55 ± 4.85 |
| percent change | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Lipoprotein(a) at Week 12 | 4.35 ± 6.86 | 7.03 ± 5.47 | -45.72 ± 6.93 | -41.74 ± 5.29 | 10.75 ± 5.15 | -5.73 ± 5.18 | -41.93 ± 5.13 | -45.70 ± 5.02 |
| percent change | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12 | 4.69 ± 6.04 | 4.54 ± 5.31 | -23.23 ± 6.15 | -17.41 ± 5.14 | -2.11 ± 4.45 | 8.06 ± 6.16 | -22.12 ± 4.44 | -12.66 ± 6.01 |
| percent change | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Triglycerides at Week 12 | 7.84 ± 7.65 | 4.34 ± 5.61 | -19.73 ± 7.74 | -15.63 ± 5.43 | -3.88 ± 4.85 | 7.30 ± 6.42 | -21.05 ± 4.82 | -9.63 ± 6.26 |
| percent change | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12 | -4.83 ± 2.25 | -1.57 ± 2.29 | 7.50 ± 2.30 | 13.05 ± 2.22 | -4.03 ± 2.34 | -3.06 ± 2.13 | 11.34 ± 2.33 | 6.09 ± 2.07 |
| percent change | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in HDL-C at Week 12 | -4.59 ± 2.58 | -0.40 ± 2.47 | 8.88 ± 2.62 | 14.80 ± 2.39 | -3.57 ± 2.59 | -2.36 ± 2.38 | 13.28 ± 2.58 | 7.84 ± 2.32 |
| percent change | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12 | 2.57 ± 5.52 | 3.10 ± 5.12 | -25.29 ± 5.65 | -19.55 ± 4.95 | -1.32 ± 4.32 | 9.96 ± 5.57 | -19.41 ± 4.31 | -17.20 ± 5.46 |
| percent change | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in VLDL-C at Week 12 | 4.09 ± 6.22 | 2.92 ± 5.45 | -24.33 ± 6.34 | -17.89 ± 5.27 | -3.03 ± 4.70 | 9.17 ± 5.63 | -18.08 ± 4.68 | -15.18 ± 5.52 |
Collected over From the first dose of blinded investigational product until the end of the study (up to 14 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| A5 Placebo Q2W | — | 1/49 (2%) | 11/49 (22.4%) |
| A5 Placebo QM | — | 2/50 (4%) | 11/50 (22%) |
| A5 Evolocumab Q2W | — | 0/50 (0%) | 13/50 (26%) |
| A5 Evolocumab QM | — | 1/50 (2%) | 9/50 (18%) |
| A20 Placebo Q2W | — | 1/52 (1.9%) | 6/52 (11.5%) |
| A20 Placebo QM | — | 1/51 (2%) | 14/51 (27.5%) |
| A20 Evolocumab Q2W | — | 0/51 (0%) | 7/51 (13.7%) |
| A20 Evolocumab QM | — | 0/51 (0%) | 12/51 (23.5%) |
| Event | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM |
|---|---|---|---|---|---|---|---|---|
| EpilepsyNervous system disorders | 1/49 | 0/50 | 0/50 | 0/50 | 0/52 | 0/51 | 0/51 | 0/51 |
| Pneumonia bacterialInfections and infestations | 0/49 | 0/50 | 0/50 | 1/50 | 0/52 | 0/51 | 0/51 | 0/51 |
| ContusionInjury, poisoning and procedural complications | 0/49 | 1/50 | 0/50 | 0/50 | 0/52 | 0/51 | 0/51 | 0/51 |
| Endometrial cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/49 | 1/50 | 0/50 | 0/50 | 0/52 | 0/51 | 0/51 | 0/51 |
| Rotator cuff syndromeMusculoskeletal and connective tissue disorders | 0/49 | 0/50 | 0/50 | 0/50 | 0/52 | 1/51 | 0/51 | 0/51 |
| Brain stem infarctionNervous system disorders | 0/49 | 0/50 | 0/50 | 0/50 | 1/52 | 0/51 | 0/51 | 0/51 |
| Event | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM |
|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 10/49 | 10/50 | 12/50 | 7/50 | 5/52 | 11/51 | 7/51 | 8/51 |
| GastroenteritisInfections and infestations | 1/49 | 0/50 | 1/50 | 2/50 | 1/52 | 0/51 | 0/51 | 3/51 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/49 | 1/50 | 1/50 | 0/50 | 0/52 | 3/51 | 1/51 | 2/51 |
Full analysis set (all randomized participants who reveid at least 1 dose of blinded investigational product).
| Age, Continuous(years) | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 62.1 ± 9.9 | 60.6 ± 9.9 | 65.2 ± 7.8 | 60.1 ± 11.6 | 60.4 ± 10.4 | 60.4 ± 10.5 | 60.1 ± 9.9 | 61.8 ± 11.9 | 61.3 ± 10.3 |
| Sex: Female, Male(Participants) | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 22 | 15 | 23 | 18 | 24 | 18 | 16 | 24 | 160 |
| Male | 27 | 35 | 27 | 32 | 28 | 33 | 35 | 27 | 244 |
| Race/Ethnicity, Customized(participants) | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 49 | 50 | 50 | 50 | 52 | 51 | 51 | 51 | 404 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stratification Factor(participants) | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diagnosis of HeFH | 3 | 2 | 2 | 3 | 3 | 2 | 3 | 3 | 21 |
| Non-HeFH and Intensive Statin Use | 10 | 10 | 11 | 10 | 11 | 11 | 11 | 11 | 85 |
| Non-HeFH and Non-Intensive Statin Use | 36 | 38 | 37 | 37 | 38 | 38 | 37 | 37 | 298 |
| LDL-C Concentration(mg/dL) | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 115.7 ± 26.0 | 114.0 ± 29.2 | 121.9 ± 44.6 | 118.8 ± 36.6 | 90.9 ± 25.5 | 90.7 ± 20.8 | 95.8 ± 23.6 | 98.0 ± 25.6 | 105.5 ± 32.0 |
| Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration(mg/dL) | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 142.0 ± 30.4 | 141.2 ± 31.8 | 151.8 ± 48.8 | 147.8 ± 39.6 | 118.2 ± 28.6 | 117.5 ± 25.1 | 121.8 ± 29.8 | 122.7 ± 29.5 | 132.7 ± 35.9 |
| Apolipoprotein B Concentration(mg/dL) | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 99.0 ± 20.0 | 100.6 ± 20.0 | 105.1 ± 31.2 | 102.2 ± 24.7 | 85.7 ± 18.4 | 82.7 ± 14.6 | 87.2 ± 19.1 | 87.7 ± 19.6 | 93.7 ± 22.8 |
| Total Cholesterol Concentration(mg/dL) | A5 Placebo Q2W | A5 Placebo QM | A5 Evolocumab Q2W | A5 Evolocumab QM | A20 Placebo Q2W | A20 Placebo QM | A20 Evolocumab Q2W | A20 Evolocumab QM | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 199.5 ± 30.7 | 199.4 ± 33.2 | 210.4 ± 47.9 | 202.5 ± 38.4 | 177.8 ± 33.0 | 173.6 ± 29.2 | 177.7 ± 26.2 | 179.0 ± 29.4 | 189.8 ± 36.3 |
6 further baseline measures are reported on the registry.
The record gives a start of Oct 2013, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2015, 1 year 6 months after primary completion. A results delay was requested in Apr 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab